Compounds > mepregenol diacetate
Page last updated: 2024-12-08

mepregenol diacetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

mepregenol diacetate: tested for use in combination with ethinyl estradiol; RN given refers to (3beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID197015
MeSH IDM0089281

Synonyms (13)

Synonym
pregna-4,6-dien-20-one, 3,17-bis(acetyloxy)-6-methyl-, (3-beta)-
diamol
pregna-4,6-dien-20-one, 3-beta,17-dihydroxy-6-methyl-, diacetate
mepregenol diacetate
acetomepregenol
1ji0g99bdo ,
unii-1ji0g99bdo
3116-07-2
pregna-4,6-dien-20-one, 3,17-bis(acetyloxy)-6-methyl-, (3.beta.)-
6-methylpregna-4,6-dien-3-.beta., 17-.alpha.-diol-20-one diacetate
(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-2,3,8,9,10,11,12,13,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3,17-diyl diacetate
Q27252498
DTXSID40953248

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"In the experiments on mature females of 50 rats, 10 rabbits, 8 dogs it was established that a new gestagenic drug acetomepregenol was not toxic both for pregnant and nonpregnant animals."( [Experimental research on the safety of the new gestagen preparation acetomepregenol].
Nikitina, GV, )		0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (66.67)18.7374
1990's2 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.79 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (9.09%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
estriol
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone. chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.		1.971016alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid		estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite
estrone
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.		1.971017-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
allylestrenol
Allylestrenol: A synthetic steroid with progestational activity.		3.3611steroid
pregnanediol
[no description available]		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		04.2741
Experimental Mammary Neoplasms
[description not available]		01.9910
Abortion, Recurrent
[description not available]		03.7621
Abortion, Threatened
UTERINE BLEEDING from a GESTATION of less than 20 weeks without any CERVICAL DILATATION. It is characterized by vaginal bleeding, lower back discomfort, or midline pelvic cramping and a risk factor for MISCARRIAGE.		04.0531
Abortion, Habitual
Three or more consecutive spontaneous abortions.		03.7621